Document is current
Any future updates will be listed below
-
Authors
Igarashi, Ataru https://orcid.org/0000-0001-6307-6916
Tachimori, Hisateru
Maruyama-Sakurai, Keiko
Segawa, Yasumasa
Takagi, Hiroyuki
Akiyama, Hiroki
Imai, Naohiko
Kohsaka, Shun
Miyata, Hiroaki
-
Funding
Funding for this research was provided by:
AstraZeneca K.K.
Program on Open Innovation Platform with Enterprises, Research Institute and Academia (JPMJOP1842)
The University of Tokyo
- License Information
-
More Information
Article History
Received: 17 December 2024
Accepted: 26 February 2025
First Online: 29 April 2025
Declarations
:
: Ataru Igarashi has received lecture fees from Astellas Pharma Inc., Bayer Yakuhin, Ltd., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corporation, MSD Co., Ltd., Novartis Pharma K.K., and Ono Pharmaceutical Co., Ltd.; and belongs to the endowed department sponsored by Takeda Pharmaceutical Co., Ltd. Hisateru Tachimori belongs to the endowed department sponsored by Takeda Pharmaceutical Co., Ltd. Hiroyuki Takagi and Hiroki Akiyama are full-time employees of AstraZeneca K.K. Shun Kohsaka has received research funding from the Japan Society for the Promotion of Science and Pfizer, and has received consulting fees from Novartis and Bristol Myers Squibb, outside of the submitted work. Hiroaki Miyata has received research funding from AstraZeneca K.K. and Mitsubishi Tanabe Pharma Corporation. Keiko Maruyama-Sakurai, Yasumasa Segawa, and Naohiko Imai have no conflicts of interest to declare.
: This study is based on previously conducted studies and published literature and does not contain any new studies with human participants or animals.
